Upsher-Smith Laboratories, LLC has launched Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP, 2.5 mg/0.025 mg. The product is an AA-rated generic version of the branded product, Lomotil* (diphenoxylate hydrochloride and atropine sulfate tablets), a combination prescription drug used to treat the symptoms of acute or chronic diarrhea. The diphenoxylate hydrochloride and atropine sulfate tablet market had U.S. sales of approximately $64 million for…
FDA Approves Klor-Con Potassium Chloride Powder For Oral Solution
Upsher-Smith Laboratories, LLC. has launched Klor-Con Powder (potassium chloride) for oral solution, 20 mEq. The company received approval of an abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) for this product, which will be marketed and distributed by Upsher-Smith. Sandoz, Inc. will continue as the licensed marketer and distributor in the U.S. for the…
Sawai Pharmaceutical To Sell 20 Percent Stake In U.S. Subsidiary To Sumitomo Corp.
Upsher-Smith’s parent company forms strategic alliance with Sumitomo Corporation in U.S. generics market. Upsher-Smith Laboratories, LLC‘s parent company, Japan-based Sawai Pharmaceutical Co., Ltd., will sell a 20 percent stake in its U.S. subsidiary (Sawai America Inc.*) to Sumitomo Corporation of Americas (SCOA), a subsidiary of Sumitomo Corporation, one of Japan’s general trading houses. Under the terms of the agreement,…